Which has better valuation & earnings, AKBA or EVO?

Akebia Therapeutics has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akebia Therapeutics $236.20M 1.05 -$5.34M -$0.08 N/A Evotec $891.97M 1.12 -$117.12M N/A N/A

Does the media prefer AKBA or EVO?

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.93 beat Evotec's score of 0.91 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AKBA or DBVT?

In the previous week, DBV Technologies had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 6 mentions for DBV Technologies and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.93 beat DBV Technologies' score of 0.41 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRVS or AKBA?

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.93 beat Corvus Pharmaceuticals' score of 0.90 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OLMA or AKBA?

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.93 beat Olema Pharmaceuticals' score of 0.38 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Akebia Therapeutics (AKBA) Competitors

$0.93 +0.00 (+0.38%)

As of 10:05 AM Eastern

Compare

AKBA vs. EVO, DBVT, CRVS, OLMA, and PHAR

Should you buy Akebia Therapeutics stock or one of its competitors? MarketBeat compares Akebia Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Akebia Therapeutics include Evotec (EVO), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Olema Pharmaceuticals (OLMA), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry.

How does Akebia Therapeutics compare to Evotec?

Akebia Therapeutics (NASDAQ:AKBA) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Akebia Therapeutics presently has a consensus price target of $4.67, indicating a potential upside of 402.87%. Evotec has a consensus price target of $7.00, indicating a potential upside of 149.11%. Given Akebia Therapeutics' higher possible upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Akebia Therapeutics has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.08	N/A
Evotec	$891.97M	1.12	-$117.12M	N/A	N/A

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Akebia Therapeutics has a net margin of -8.83% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Evotec	-26.20%	-24.93%	-11.35%

Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Evotec has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.93 beat Evotec's score of 0.91 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Akebia Therapeutics beats Evotec on 7 of the 12 factors compared between the two stocks.

How does Akebia Therapeutics compare to DBV Technologies?

Akebia Therapeutics (NASDAQ:AKBA) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Akebia Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

Akebia Therapeutics has a net margin of -8.83% compared to DBV Technologies' net margin of -2,895.37%. Akebia Therapeutics' return on equity of -62.72% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

In the previous week, DBV Technologies had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 6 mentions for DBV Technologies and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.93 beat DBV Technologies' score of 0.41 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics currently has a consensus price target of $4.67, indicating a potential upside of 402.87%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 173.39%. Given Akebia Therapeutics' higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Akebia Therapeutics has higher revenue and earnings than DBV Technologies. Akebia Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.08	N/A
DBV Technologies	$5.64M	186.24	-$146.95M	-$4.46	N/A

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Akebia Therapeutics beats DBV Technologies on 10 of the 17 factors compared between the two stocks.

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Corvus Pharmaceuticals presently has a consensus price target of $33.33, suggesting a potential upside of 169.97%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 402.87%. Given Akebia Therapeutics' higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.93 beat Corvus Pharmaceuticals' score of 0.90 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Corvus Pharmaceuticals' return on equity of -38.92% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Akebia Therapeutics has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.08	N/A

Summary

Corvus Pharmaceuticals beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Olema Pharmaceuticals has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Olema Pharmaceuticals' return on equity of -46.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.93 beat Olema Pharmaceuticals' score of 0.38 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.08	N/A

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Olema Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Olema Pharmaceuticals currently has a consensus target price of $44.10, suggesting a potential upside of 338.06%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 402.87%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Olema Pharmaceuticals beats Akebia Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Pharming Group?

Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Akebia Therapeutics currently has a consensus price target of $4.67, indicating a potential upside of 402.87%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 196.90%. Given Akebia Therapeutics' higher possible upside, equities analysts clearly believe Akebia Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Akebia Therapeutics had 2 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for Akebia Therapeutics and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.87 beat Akebia Therapeutics' score of 0.93 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Akebia Therapeutics	Positive
Pharming Group	Very Positive

Pharming Group has a net margin of 3.30% compared to Akebia Therapeutics' net margin of -8.83%. Pharming Group's return on equity of 4.64% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Pharming Group	3.30%	4.64%	2.55%

Pharming Group has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.08	N/A
Pharming Group	$369.49M	2.47	$2.85M	$0.16	80.69

Akebia Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pharming Group beats Akebia Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$248.95M	$2.99B	$6.49B	$12.31B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-11.60	18.81	24.05	24.76
Price / Sales	1.05	468.63	542.61	168.32
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	7.73	4.01	10.69	6.90
Net Income	-$5.34M	$75.79M	$3.57B	$337.45M
7 Day Performance	-0.81%	2.78%	1.56%	2.84%
1 Month Performance	-12.45%	0.52%	2.49%	4.78%
1 Year Performance	-73.93%	24.68%	26.51%	33.08%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	1.8713 of 5 stars	$0.93 +0.4%	$4.67 +402.9%	-74.0%	$248.95M	$236.20M	N/A	430	Gap Down
EVO Evotec	2.3666 of 5 stars	$2.81 +0.4%	$7.00 +149.1%	-36.3%	$996.12M	$891.97M	N/A	4,553
DBVT DBV Technologies	3.4009 of 5 stars	$16.00 -3.6%	$48.50 +203.1%	+91.4%	$982.27M	$5.64M	N/A	80	News Coverage Gap Up
CRVS Corvus Pharmaceuticals	2.8498 of 5 stars	$11.15 +0.3%	$33.33 +199.0%	+184.7%	$935.09M	N/A	N/A	30
OLMA Olema Pharmaceuticals	2.5241 of 5 stars	$9.96 -3.4%	$44.10 +342.8%	+136.7%	$900.55M	N/A	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. EVO, DBVT, CRVS, OLMA, and PHAR

How does Akebia Therapeutics compare to Evotec?

Summary

How does Akebia Therapeutics compare to DBV Technologies?

Summary

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Akebia Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Akebia Therapeutics compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. EVO, DBVT, CRVS, OLMA, and PHAR

How does Akebia Therapeutics compare to Evotec?

Do analysts prefer AKBA or EVO?

Which has better valuation & earnings, AKBA or EVO?

Do insiders and institutionals believe in AKBA or EVO?

Is AKBA or EVO more profitable?

Which has more volatility and risk, AKBA or EVO?

Does the media prefer AKBA or EVO?

Summary

How does Akebia Therapeutics compare to DBV Technologies?

Which has more volatility & risk, AKBA or DBVT?

Is AKBA or DBVT more profitable?

Does the media refer more to AKBA or DBVT?

Do analysts prefer AKBA or DBVT?

Which has preferable valuation & earnings, AKBA or DBVT?

Do institutionals and insiders believe in AKBA or DBVT?

Summary

How does Akebia Therapeutics compare to Corvus Pharmaceuticals?

Do analysts rate CRVS or AKBA?

Does the media prefer CRVS or AKBA?

Do insiders & institutionals have more ownership in CRVS or AKBA?

Which has more risk & volatility, CRVS or AKBA?

Is CRVS or AKBA more profitable?

Which has stronger valuation & earnings, CRVS or AKBA?

Summary

How does Akebia Therapeutics compare to Olema Pharmaceuticals?

Is OLMA or AKBA more profitable?

Does the media refer more to OLMA or AKBA?

Which has better earnings and valuation, OLMA or AKBA?

Do institutionals and insiders have more ownership in OLMA or AKBA?

Which has more volatility and risk, OLMA or AKBA?

Do analysts prefer OLMA or AKBA?

Summary

How does Akebia Therapeutics compare to Pharming Group?

Do analysts prefer AKBA or PHAR?

Does the media favor AKBA or PHAR?

Is AKBA or PHAR more profitable?

Which has stronger valuation & earnings, AKBA or PHAR?

Which has more volatility and risk, AKBA or PHAR?

Do insiders and institutionals believe in AKBA or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools